The number of disease modifying therapies (DMTs) available to treat multiple sclerosis (MS) has expanded greatly over the last ten years. Although some of the newer DMTs are associated with better control compared to older injectable therapy, they are also associated with more complex safety profiles and specific monitoring requirements.
This program reviews the safety profiles of DMTs and summarizes their monitoring requirements, with the goal of supporting clinicians in optimizing the safety of MS therapy.
This program has received an unrestricted educational grant or in-kind support from Roche.